- Home
- FRVO vs MDGL Comparison
FRVO vs MDGL Comparison
Compare FRVO & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$431.18
Company Overview
Basic Information| Metric | FRVO | MDGL |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 11.5B |
| IPO Year | 2026 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FRVO | MDGL |
|---|---|---|
| Price | $8.32 | $431.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | $34.92 | ★ $685.22 |
| AVG Volume (30 Days) | ★ 8.7M | 270.3K |
| Earning Date | 11-19-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $4,307.57 | $59.43 |
| Revenue Next Year | $1,080.49 | $38.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.72 | $399.00 |
| 52 Week High | $41.42 | $615.00 |
Technical Indicators
Market Signals| Indicator | FRVO | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 26.90 | 28.45 |
| Support Level | N/A | $416.21 |
| Resistance Level | $18.54 | $546.29 |
| Average True Range (ATR) | 0.75 | 15.89 |
| MACD | -0.11 | -1.72 |
| Stochastic Oscillator | 7.97 | 3.36 |
Price Performance
Historical Comparison FRVO
MDGL
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.